Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Q2 2020 Earnings Conference Call - Final Transcript
Jul 30, 2020 • 04:30 pm ET
REMS program and allergists starting new patients on PALFORZIA. Our practice account managers, or PAMs, began more broadly engaging with allergists in person, once again, to assist them with REMS certifications, train them and provide additional educational resources. This trend has continued through July.
As of today, nearly 1,000 allergists and 600 allergy practices are REMS-certified. Approximately 100 allergists have enrolled patients in the REMS program, and half of these allergists have enrolled more than one patient. We are seeing some clinics beginning to fully operationalize PALFORZIA at scale with double-digit numbers of new patient starts. These REMS enrollment figures represent a sharp increase since May, and we view these statistics as encouraging signs for the future uptake of PALFORZIA.
I'd like to share with you a couple of the many anecdotes that we've received from the field force this quarter that reflect the enthusiasm for PALFORZIA from both allergists and caregivers. One clinic with an estimated 200 peanut-allergic patients created an educational post for caregivers about OIT on their website. They received so many calls from interested parents that they had to designate a separate phone and line and an office representative to start a wait list. Another allergist with over 150 pediatric peanut-allergic patients planned to notify all of them about PALFORZIA in two waves of mail-outs to their parents. The first 100 letters sent led to an overwhelming response, and the allergist is now scheduling patients for treatment. These are just a few of many such anecdotes, and we are very encouraged by them as they reflect the burden of disease and the need for a therapy for patients with peanut allergy.
We recently initiated a targeted consumer marketing campaign to create awareness of PALFORZIA among patients and caregivers. We've also continued to make significant progress with payers, which will be invaluable as more physicians start to treat patients with PALFORZIA. Andrew will provide more detail on these topics in a few minutes.
We expect allergy practices to increasingly introduce PALFORZIA to their patients over the next few months. Although the country is still grappling with COVID-19, and we are in uncharted territory, we don't anticipate allergists shutting down their practices completely, as they did in March and April, since they have learned to adapt to this new environment. Overall, we're optimistic and excited about the progress we're making on behalf of patients with food allergies. We are carefully balancing launch activities, pipeline advancement and cash preservation. We remain confident in our prospects and steadfast in our mission to improve the lives of people with food allergies.
I'll now turn the call over to Dan to discuss recently presented clinical data and our pipeline.
Daniel C. Adelman
Thank you, Jayson. We presented 18-month and two-year PALFORZIA data from our ARC004 study at the European Academy of Allergy and Clinical Immunology or EAACI meeting, which was held online at the beginning of June. The data we presented demonstrated ongoing immunomodulation during the first two years of daily treatment with PALFORZIA and